These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

332 related articles for article (PubMed ID: 25018629)

  • 21. Roflumilast in the management of chronic obstructive pulmonary disease.
    Lipari M; Benipal H; Kale-Pradhan P
    Am J Health Syst Pharm; 2013 Dec; 70(23):2087-95. PubMed ID: 24249758
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Risk factors for the discontinuation of roflumilast in patients with chronic obstructive pulmonary disease.
    Kim KH; Kang HS; Kim JS; Yoon HK; Kim SK; Rhee CK
    Int J Chron Obstruct Pulmon Dis; 2017; 12():3449-3456. PubMed ID: 29270006
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Roflumilast: first phosphodiesterase 4 inhibitor approved for treatment of COPD.
    Giembycz MA; Field SK
    Drug Des Devel Ther; 2010 Jul; 4():147-58. PubMed ID: 20689641
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Roflumilast added to triple therapy in patients with severe COPD: a real life study.
    Muñoz-Esquerre M; Diez-Ferrer M; Montón C; Pomares X; López-Sánchez M; Huertas D; Manresa F; Dorca J; Santos S
    Pulm Pharmacol Ther; 2015 Feb; 30():16-21. PubMed ID: 25445930
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Modeling and Simulation of Pivotal Clinical Trials Using Linked Models for Multiple Endpoints in Chronic Obstructive Pulmonary Disease With Roflumilast.
    Facius A; Krause A; Claret L; Bruno R; Lahu G
    J Clin Pharmacol; 2017 Aug; 57(8):1042-1052. PubMed ID: 28419462
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Can roflumilast, a phosphodiesterase-4 inhibitor, improve clinical outcomes in patients with moderate-to-severe chronic obstructive pulmonary disease? A meta-analysis.
    Luo J; Wang K; Liu D; Liang BM; Liu CT
    Respir Res; 2016 Feb; 17():18. PubMed ID: 26887407
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Roflumilast: doubtful efficacy but clear harms in COPD.
    Prescrire Int; 2013 Jan; 22(134):5-9. PubMed ID: 23367674
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Phosphodiesterase 4 inhibitors for chronic obstructive pulmonary disease.
    Chong J; Leung B; Poole P
    Cochrane Database Syst Rev; 2017 Sep; 9(9):CD002309. PubMed ID: 28922692
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Reduce disease burden and improve lung function-roflumilast: approved for moderate to severe COPD: update for the clinical nurse specialist.
    O'Malley P
    Clin Nurse Spec; 2011; 25(4):176-7. PubMed ID: 21654371
    [No Abstract]   [Full Text] [Related]  

  • 30. New therapeutic options in the management of COPD - focus on roflumilast.
    Antoniu SA
    Int J Chron Obstruct Pulmon Dis; 2011; 6():147-55. PubMed ID: 21468165
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Roflumilast in Asian patients with COPD: A randomized placebo-controlled trial.
    Lee SD; Hui DS; Mahayiddin AA; Roa CC; Kwa KH; Goehring UM; Bredenbröker D; Kuo HP
    Respirology; 2011 Nov; 16(8):1249-57. PubMed ID: 21848706
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A 1-year prospective cost-effectiveness analysis of roflumilast for the treatment of patients with severe chronic obstructive pulmonary disease.
    Rutten-van Mölken MP; van Nooten FE; Lindemann M; Caeser M; Calverley PM
    Pharmacoeconomics; 2007; 25(8):695-711. PubMed ID: 17640111
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Benefits and harms of roflumilast in moderate to severe COPD.
    Yu T; Fain K; Boyd CM; Singh S; Weiss CO; Li T; Varadhan R; Puhan MA
    Thorax; 2014 Jul; 69(7):616-22. PubMed ID: 24347460
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Efficacy and Safety of Roflumilast in Korean Patients with COPD.
    Lee JS; Hong YK; Park TS; Lee SW; Oh YM; Lee SD
    Yonsei Med J; 2016 Jul; 57(4):928-35. PubMed ID: 27189287
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Phosphodiesterase 4 inhibitors for chronic obstructive pulmonary disease.
    Chong J; Leung B; Poole P
    Cochrane Database Syst Rev; 2013 Nov; (11):CD002309. PubMed ID: 24190161
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A Randomized, Placebo-controlled Trial of Roflumilast. Effect on Proline-Glycine-Proline and Neutrophilic Inflammation in Chronic Obstructive Pulmonary Disease.
    Wells JM; Jackson PL; Viera L; Bhatt SP; Gautney J; Handley G; King RW; Xu X; Gaggar A; Bailey WC; Dransfield MT; Blalock JE
    Am J Respir Crit Care Med; 2015 Oct; 192(8):934-42. PubMed ID: 26151090
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Roflumilast for the treatment of COPD in an Asian population: a randomized, double-blind, parallel-group study.
    Zheng J; Yang J; Zhou X; Zhao L; Hui F; Wang H; Bai C; Chen P; Li H; Kang J; Brose M; Richard F; Goehring UM; Zhong N
    Chest; 2014 Jan; 145(1):44-52. PubMed ID: 24135893
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Roflumilast--a phosphodiesterase-4 inhibitor licensed for add-on therapy in severe COPD.
    Taegtmeyer AB; Leuppi JD; Kullak-Ublick GA
    Swiss Med Wkly; 2012; 142():w13628. PubMed ID: 22833385
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Drug safety evaluation of roflumilast for the treatment of COPD: a meta-analysis.
    Rogliani P; Calzetta L; Cazzola M; Matera MG
    Expert Opin Drug Saf; 2016 Aug; 15(8):1133-46. PubMed ID: 27279341
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effect of ensifentrine on dyspnea in patients with moderate-to-severe chronic obstructive pulmonary disease: pooled analysis of the ENHANCE trials.
    Mahler DA; Bhatt SP; Rheault T; Reyner D; Bengtsson T; Dixon A; Rickard K; Singh D
    Expert Rev Respir Med; 2024 Aug; 18(8):645-654. PubMed ID: 39106052
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.